UBS Increases Micron and Nasdaq Call Options in Q2 While Expanding S&P Put Option Hedges
Nashnova编辑部
UBS grew its U.S. equity book to $790 billion in Q2, adding aggressively to Micron calls and Nasdaq calls for AI-storage upside while boosting S&P 500 puts by 155% — a textbook barbell that bets on momentum and buys crash insurance at the same time.
How much did UBS's overall position change this quarter?
Total portfolio market value rose from $670 billion to $790 billion, up roughly 18% quarter-over-quarter and approaching the trillion-dollar mark.
This means → UBS is not pulling back; it is actively adding risk — but the direction of that risk is very deliberate.
The top five additions were: Eli Lilly calls, S&P 500 ETF (SPY) puts, Micron common stock, Micron calls, and Nasdaq 100 ETF (QQQ) calls — bullish and bearish bets sitting side by side at the top of the list.
Why the heavy bet on Micron and Nasdaq calls?
Micron call options surged 174.94% in notional-equivalent terms, making it one of the quarter's largest derivative moves; Micron common stock stood at roughly 6.09 million shares, the eleventh-largest holding.
In plain terms = UBS is betting that after GPU compute, memory becomes AI's second scarce bottleneck — and it wants in early.
Nasdaq 100 ETF calls (QQQ calls) rose 90.40% to roughly 9.69 million share-equivalents, with a reported value of about $7.14 billion, vaulting into the top ten.
This means → rather than piling more money into a single crowded name like Nvidia, UBS used QQQ calls to capture broad AI-ecosystem upside in one position.
How is the downside protection structured alongside the longs?
S&P 500 ETF puts (SPY puts) jumped roughly 155.10%, rising to the eighth-largest holding at about 11.29 million share-equivalents and a reported value of approximately $8.43 billion.
Nasdaq 100 ETF puts (QQQ puts) also grew by about 10%.
In plain terms = adding puts on both major indexes is essentially buying an insurance policy against a sudden deleveraging of the crowded AI trade.
Why did Eli Lilly calls explode by 4,571%?
Eli Lilly calls leapt to the seventh-largest holding — roughly 7.30 million share-equivalents, reported value about $8.76 billion, up 4,571.11% from the prior quarter.
This means → Lilly is a healthcare-growth name with low correlation to the AI capex cycle and strong fundamental visibility — UBS is using it to hedge a broad tech-sector drawdown.
This reflects a layered approach: UBS is not relying on index puts alone but also diversifying at the asset-class level — if tech falls, healthcare doesn't necessarily follow.
What do the top holdings and key sell-downs tell us?
Nvidia remains the largest position at roughly 83.07 million shares and about $16.62 billion, though it was trimmed by 0.12%; Apple, Microsoft, Broadcom, and Alphabet round out the top five, all modestly added.
The five biggest sell-downs: ExxonMobil, Meta Platforms, high-yield corporate bond ETF puts, gold ETF puts, and gold ETF calls — tactical positions previously used for macro-tail and commodity-volatility trades were systematically wound down.
In plain terms = the core Q2 signal is not "exiting tech" but rotating from a crowded single-name AI-compute bet into storage, cloud, and broader AI beta — while swapping gold and commodity hedges for index puts and healthcare growth.
What should we watch next for this barbell to pay off?
Whether the heavy Micron-call position delivers depends on structural growth in memory demand being confirmed in coming quarters — that is the key checkpoint.
This means → if AI demand for high-bandwidth memory (HBM) keeps beating expectations, the Micron calls are early positioning; if demand softens, the time value of those options will erode fast.
This reflects a shift in UBS's thesis from "which AI company wins" to "where is the next bottleneck in the AI supply chain."
Content is for reference only, not financial advice.